Alnylam Pharmaceuticals (ALNY) Raw Materials (2018 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Raw Materials came in at $13.9 million in Q2 2026, down 39.16% YoY from $22.9 million in Q2 2025, and up 19.05% on a QoQ basis from $11.7 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Raw Materials (2018 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 9 years of Raw Materials data on file, last reported at $13.9 million in Q2 2026.
- Quarterly Raw Materials fell 39.16% year-over-year to $13.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $13.9 million (down 39.16% YoY) and the FY2025 annual result came in at $14.2 million, down 40.81% from the prior year.
- Raw Materials grew to $13.9 million in Q2 2026, from $11.7 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $26.0 million in Q2 2024 to a low of $11.7 million in Q1 2026.
- A 5-year average of $20.5 million and a median of $22.3 million in 2022 frame the typical range for Raw Materials.
- The widest YoY moves for Raw Materials: up 51.25% in 2022, down 72.81% in 2022.
- Tracing ALNY's Raw Materials over 5 years: stood at $22.3 million in 2022, then rose by 4.62% to $23.3 million in 2023, then increased by 2.65% to $24.0 million in 2024, then sank by 40.81% to $14.2 million in 2025, then dropped by 1.91% to $13.9 million in 2026.
- The last three Raw Materials figures came in at $13.9 million (Q2 2026), $11.7 million (Q1 2026), and $14.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.91 Mn |
| Mar 31, 2026 | 11.69 Mn |
| Dec 31, 2025 | 14.18 Mn |
| Sep 30, 2025 | 22.25 Mn |
| Jun 30, 2025 | 22.87 Mn |
| Mar 31, 2025 | 23.40 Mn |
| Dec 31, 2024 | 23.97 Mn |
| Sep 30, 2024 | 22.37 Mn |
| Jun 30, 2024 | 26.02 Mn |
| Mar 31, 2024 | 25.40 Mn |
| Dec 31, 2023 | 23.35 Mn |
| Sep 30, 2023 | 20.12 Mn |
| Jun 30, 2023 | 17.45 Mn |
| Mar 31, 2023 | 22.88 Mn |
| Dec 31, 2022 | 22.32 Mn |
| Sep 30, 2022 | 17.72 Mn |
| Jun 30, 2022 | 19.14 Mn |
| Mar 31, 2022 | 20.37 Mn |
| Dec 31, 2021 | 14.75 Mn |
| Sep 30, 2021 | 65.16 Mn |